Alliance Global Partners Weighs in on Organigram Q3 Earnings

Organigram Holdings Inc. (TSE:OGI) – Alliance Global Partners raised their Q3 2025 earnings estimates for shares of Organigram in a report issued on Tuesday, February 11th. Alliance Global Partners analyst A. Grey now anticipates that the company will earn ($0.03) per share for the quarter, up from their prior forecast of ($0.04). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.26) EPS and FY2026 earnings at ($0.08) EPS.

Other equities analysts have also issued research reports about the company. ATB Capital cut their price target on Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th. Canaccord Genuity Group reduced their target price on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research note on Monday, December 9th.

Organigram Price Performance

Shares of OGI stock opened at C$1.92 on Friday. The company has a current ratio of 3.36, a quick ratio of 2.62 and a debt-to-equity ratio of 3.07. The firm has a market capitalization of C$237.20 million, a price-to-earnings ratio of -4.06, a PEG ratio of 0.42 and a beta of 1.13. The firm’s 50 day moving average is C$2.24 and its 200-day moving average is C$2.32. Organigram has a 1 year low of C$1.86 and a 1 year high of C$3.95.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.